Canaccord Adams initiates coverage on AtriCure (Nasdaq: ATRC) with a Buy rating and a $15 price target.

The firm ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE